V
Veralox Therapeutics
Veralox Therapeutics is a small molecule drug discovery and development firm based in the Frederick Innovative Technology Center, Inc
About Veralox Therapeutics
Veralox Therapeutics is a biotechnology company focused on developing innovative small molecule therapeutics that address the underlying causes of thrombosis and type 1 diabetes. By leveraging a deep understanding of the molecular mechanisms driving these diseases, Veralox aims to create new treatment paradigms that significantly improve patient outcomes. The company operates in the biopharmaceutical market, primarily serving patients with unmet medical needs. Veralox's business model involves the research, development, and commercialization of novel therapeutics, generating revenue through product sales, partnerships, and potential licensing agreements. The recent FDA Orphan Drug Designation for VLX 1005 and a successful Series A financing round underscore the company's growth and potential impact in the healthcare sector.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 57.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Drug Development, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- B2B
- Investment activity
- 1 company, latest Jan 2025
- Capital deployed
- —
- Preferred round
- ACQUISITION
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Jun 2023 | $24M | $96M | Hatteras Venture Partners · Sanofi Ventures · NYBC Ventures · Pappas Capital | ↗ |
| SERIES A✓Equity / VC | Jun 2021 | $17M | $66M | Virginia Tech Carilion (VTC) Innovation Fund · Genesys Capital · Point Field Partners · Hatteras Venture Partners | — |
Growth signals
Latest recorded traffic for Veralox Therapeutics is 860 monthly website visits, down 38.6% over the last three months. Veralox Therapeutics's team declined 25% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Veralox Therapeutics in the Frederick ecosystem
The Veralox Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
- VFVTC Seed Fund
Sanofi Ventures
Virginia Tech Carilion (VTC) Innovation Fund
JDRF T1D Fund
Series A8 investors entered at this stage
Hatteras Venture Partners
Genesys Capital
Point Field Partners
TEDCO
Alexandria Venture Investments
Maryland Momentum Fund
NYBC Ventures
Pappas Capital
Other known investors4 additional known investors
Eastern Virginia Medical School
National Institutes of Health
Alumni Ventures
VTC Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Veralox Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Veralox Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









